Fed. Circ. Affirms Sandoz Loss In Generic AzaSite Case
The Federal Circuit on Thursday affirmed a lower court's ruling barring Sandoz Inc. from marketing a generic version of the eye infection drug AzaSite, ruling that the company has failed to...To view the full article, register now.
Already a subscriber? Click here to view full article